ADDF Drug Development RFP (formerly Drug Discovery Program)
Alzheimer's Drug Discovery Foundation (ADDF) · Foundation
Source: Alzheimer's Drug Discovery Foundation (ADDF) (curated) · View original posting ↗
Current cycle LOI due September 14, 2026. Funding is structured as a mission-related investment, not a conventional grant.
- AwardWhat a single award can be worth — the funder's published per-award amount or floor–ceiling range.
- Up to $5M
- DeadlineFinal application due date.
- Not set
- Letter of intentDue date for the letter of intent (a short pre-application some funders require or request before the full proposal).
- Sep 14, 2026
- MechanismNIH activity code — the grant type (R01 research project, R21 exploratory, K series career development, F series fellowship, …).
- —
- DurationMaximum project period for a single award.
- 2 yr
- Expected awardsHow many awards the funder anticipates making under this opportunity.
- —
- Funding cycleHow often the program accepts applications (annual, multiple cycles per year, rolling, or one-time).
- Recurring (annual)
- Open dateWhen applications open (or opened).
- —
- Total fundingThe overall pool the funder expects to commit across ALL awards under this opportunity — not what one project receives.
- —
- Clinical trialWhether proposed projects must, may, or must not include a clinical trial.
- Optional / allowed
Research areas
Auto-classified from the title and description (keyword-based) — may be imperfect.
Description
Funds drug development for Alzheimer's and related dementias, scoped to IND-enabling studies and early-phase clinical trials (lead optimization and candidate selection are explicitly excluded). Awards up to $5,000,000. Curated entry; verify current terms at the program page.
This funder has no public API, so the entry is manually curated — confirm current amounts, deadlines, and eligibility on the source page.